Prevention of cardiac Arrhythmias by the oral administration of flecainide acetate
Jelena Stamenkovic-Rebic, Andjelija Necin, Zivojin
Stamenkovic. Cardiovascular Dispensary, Novi Sad, Serbia.
Flecainide acetate is the antiarrhythmic (Class Ic)
which is extremely effective in converting auricular and ventricular
arrhyfhmias.
The aim of this study was to asses the effect of Flecainide (F) in
patients (pts) with ischemic heart disease and ventricular premature complexes
(VPC). After the partial success of treatment with Fulguration, 14 pts (mean age
46.2 ± 10.2 yrs) were treated with F (200-400 mg per day) for 30 days. Before
the treatment of F we administered Placebo for 5 days.
Methods: All pts underwent ECG examination, electrocardiographic
monitoring (24-hour holter monitoring), and electrophysiological studies, before
and after treatment with F. We followed effectiveness of F on QRS duration, QT
interval, effective refractory periods (ERP) of the right atrium(RA),
atrioventricular nodal conduction time (AH interval) and Hiss-Purcinje
conduction time (HV interval).
Results are presented on the table:
|
Before th |
After th |
||
|
QRS duration (sec) |
0.05±0.001 |
0.065±0.001 |
<0.001 |
|
QT interval (sec) |
0.38±0.04 |
04l±0.04 |
<0.05 |
|
ERP (RA) (msec) |
250.4±12.4 |
300.4±15.5 |
<0.001 |
|
AH interval (msec) |
84.4±10.1 |
102.4±10.4 |
<0.001 |
|
HV interval (msec) |
51.9±10.1 |
70.4±12.7 |
<0.001 |
Number of VPC after th with F decreased for 17%.
Conclusion: In pts with ischemic heart diseases and ventricular premature complexes, after the partial success of treatment with Fulguration, the heart rhythm has been successfully regulated by the administration of Flecainide. F decreased a number of VPC.
Search Internet
|
copyright a.s. |